EirGenix Inc. (TPE:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
56.70
-1.00 (-1.73%)
At close: Mar 13, 2026
Market Cap17.16B -30.7%
Revenue (ttm)1.01B -20.0%
Net Income-760.55M
EPS-2.51
Shares Out302.60M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume529,648
Average Volume510,655
Open56.70
Previous Close57.70
Day's Range56.60 - 57.60
52-Week Range52.70 - 84.30
Beta0.67
RSI36.44
Earnings DateMar 18, 2026

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 1,000
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.

Financial Statements